Your browser doesn't support javascript.
loading
Structure-based design of bitopic ligands for the µ-opioid receptor.
Faouzi, Abdelfattah; Wang, Haoqing; Zaidi, Saheem A; DiBerto, Jeffrey F; Che, Tao; Qu, Qianhui; Robertson, Michael J; Madasu, Manish K; El Daibani, Amal; Varga, Balazs R; Zhang, Tiffany; Ruiz, Claudia; Liu, Shan; Xu, Jin; Appourchaux, Kevin; Slocum, Samuel T; Eans, Shainnel O; Cameron, Michael D; Al-Hasani, Ream; Pan, Ying Xian; Roth, Bryan L; McLaughlin, Jay P; Skiniotis, Georgios; Katritch, Vsevolod; Kobilka, Brian K; Majumdar, Susruta.
Afiliação
  • Faouzi A; Center for Clinical Pharmacology, University of Health Sciences and Pharmacy and Washington University School of Medicine, St Louis, MO, USA.
  • Wang H; Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.
  • Zaidi SA; Department of Quantitative and Computational Biology, Department of Chemistry, Bridge Institute and Michelson Center for Convergent Bioscience, University of Southern California, Los Angeles, CA, USA.
  • DiBerto JF; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
  • Che T; Center for Clinical Pharmacology, University of Health Sciences and Pharmacy and Washington University School of Medicine, St Louis, MO, USA.
  • Qu Q; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
  • Robertson MJ; Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.
  • Madasu MK; Department of Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.
  • El Daibani A; Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA, USA.
  • Varga BR; Department of Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.
  • Zhang T; Center for Clinical Pharmacology, University of Health Sciences and Pharmacy and Washington University School of Medicine, St Louis, MO, USA.
  • Ruiz C; Center for Clinical Pharmacology, University of Health Sciences and Pharmacy and Washington University School of Medicine, St Louis, MO, USA.
  • Liu S; Center for Clinical Pharmacology, University of Health Sciences and Pharmacy and Washington University School of Medicine, St Louis, MO, USA.
  • Xu J; Department of Neurology and Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Appourchaux K; Department of Chemistry, Scripps Research, Jupiter, FL, USA.
  • Slocum ST; Department of Anesthesiology, Rutgers New Jersey Medical School, Newark, NJ, USA.
  • Eans SO; Department of Anesthesiology, Rutgers New Jersey Medical School, Newark, NJ, USA.
  • Cameron MD; Center for Clinical Pharmacology, University of Health Sciences and Pharmacy and Washington University School of Medicine, St Louis, MO, USA.
  • Al-Hasani R; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
  • Pan YX; Department of Pharmacodynamics, University of Florida, Gainesville, FL, USA.
  • Roth BL; Department of Chemistry, Scripps Research, Jupiter, FL, USA.
  • McLaughlin JP; Center for Clinical Pharmacology, University of Health Sciences and Pharmacy and Washington University School of Medicine, St Louis, MO, USA.
  • Skiniotis G; Department of Neurology and Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Katritch V; Department of Anesthesiology, Rutgers New Jersey Medical School, Newark, NJ, USA.
  • Kobilka BK; Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
  • Majumdar S; Department of Pharmacodynamics, University of Florida, Gainesville, FL, USA.
Nature ; 613(7945): 767-774, 2023 01.
Article em En | MEDLINE | ID: mdl-36450356
ABSTRACT
Mu-opioid receptor (µOR) agonists such as fentanyl have long been used for pain management, but are considered a major public health concern owing to their adverse side effects, including lethal overdose1. Here, in an effort to design safer therapeutic agents, we report an approach targeting a conserved sodium ion-binding site2 found in µOR3 and many other class A G-protein-coupled receptors with bitopic fentanyl derivatives that are functionalized via a linker with a positively charged guanidino group. Cryo-electron microscopy structures of the most potent bitopic ligands in complex with µOR highlight the key interactions between the guanidine of the ligands and the key Asp2.50 residue in the Na+ site. Two bitopics (C5 and C6 guano) maintain nanomolar potency and high efficacy at Gi subtypes and show strongly reduced arrestin recruitment-one (C6 guano) also shows the lowest Gz efficacy among the panel of µOR agonists, including partial and biased morphinan and fentanyl analogues. In mice, C6 guano displayed µOR-dependent antinociception with attenuated adverse effects, supporting the µOR sodium ion-binding site as a potential target for the design of safer analgesics. In general, our study suggests that bitopic ligands that engage the sodium ion-binding pocket in class A G-protein-coupled receptors can be designed to control their efficacy and functional selectivity profiles for Gi, Go and Gz subtypes and arrestins, thus modulating their in vivo pharmacology.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Desenho de Fármacos / Fentanila / Receptores Opioides mu / Morfinanos Limite: Animals Idioma: En Revista: Nature Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Desenho de Fármacos / Fentanila / Receptores Opioides mu / Morfinanos Limite: Animals Idioma: En Revista: Nature Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos